Mesa Laboratories'' bottom-line fundamentals have been weakening on a sequential basis. Read more to see why I recommend MLAB a hold.
→ Google ترجمة
https://www.investing.com/news/pro/mesa-laboratories-pt-lowered-to-180-at-evercore-isi-432SI-2870094
→ Google ترجمة
The following slide deck was published by Mesa Laboratories, Inc.
→ Google ترجمة
Mesa Laboratories (NASDAQ: MLAB ) reported its Q1 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Mesa Laboratories beat estimated earnings by 18.18%, reporting an EPS of $1.17 versus … Full story available on Benzinga.com
→ Google ترجمة
Mesa Laboratories press release (MLAB): Q1 GAAP EPS of -$0.27 misses by $0.27.Revenue of $50.45M (+44.5% Y/Y) misses by $1.72M.
→ Google ترجمة
In a recent SEC filing, a top shareholder of pharmaceutical instruments manufacturer Mesa Laboratories, Inc. (NASDAQ: MLAB), John James Sullivan, revealed that he bought 18,576 shares of the company for over $2.09 million on July 5. Shares of the company slipped 1.4% to close at $201.66 on Wednesday. According to the SEC filing, Sullivan, also a Director of the company, lapped up the above-mentioned number of shares in two transactions. He bought 3,576 shares at an average price of $70.56 per share and then bought 15,000 shares at a per-share price of $122.66. Sullivan now owns 43,450 shares of the company.
→ Google ترجمة
Mesa Laboratories (NASDAQ:MLAB) declares $0.16/share quarterly dividend, in line with previous.Forward yield 0.32%Payable Sept. 15; for shareholders of record Aug. 31; ex-div Aug.
→ Google ترجمة
Lakewood, CO, July 06, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2022, to shareholders of record at the close of business on August 31, 2022.
→ Google ترجمة
Mesa Laboratories (NASDAQ: MLAB ) reported its Q4 earnings results on Tuesday, May 31, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Mesa Laboratories beat estimated earnings by 362.5%, reporting an EPS of $2.22 versus … Full story available on Benzinga.com
→ Google ترجمة
Mesa Laboratories press release (MLAB): Q4 GAAP EPS of -$0.34 misses by $0.82.Revenue of $58.88M (+55.1% Y/Y) beats by $2.58M.
→ Google ترجمة
Mesa Laboratories (MLAB) had declared $0.16/share quarterly dividend, in line with previous. Payable June 15; for shareholders of record May 31; ex-div May 27.
→ Google ترجمة
LAKEWOOD, Colo., July 06, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, Mesa Labs or the Company) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2021, to shareholders of record at the close of business on August 31, 2021.
→ Google ترجمة
The Insight Partners announces the research on Global Sterilization Monitoring Market as it covers the key boundaries required for your Research Need. This Global Sterilization Monitoring Market Report covers worldwide, []
→ Google ترجمة
DUBLIN--(BUSINESS WIRE)--The "Global Sterilization Monitoring Market (2021-2026) by Technology, Product, Method of Sterilization, Process, End-user, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Sterilization Monitoring Market is estimated to be USD 590.7 Mn in 2021 and is expected to reach USD 876.1 Mn by 2026, growing at a CAGR of 8.2%. The Global Sterilization Monitoring Market is segmen
→ Google ترجمة
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hologic (HOLX) and Mesa Laboratories The post Analysts Offer Insights on Healthcare Companies: Hologic (HOLX) and Mesa Laboratories (MLAB) appeared first on Smarter Analyst .
→ Google ترجمة
Top Players Covered in the Steam and Hydrogen Peroxide Biological Indicators Market Research Report are 3M (Minnesota, U.S.), STERIS (Ohio, United States), Getinge AB (Sweden), Cantel Medical (New Jersey, U.S.), Mesa Labs, Inc. (Colorado, United States), Tuttnauer (Hauppauge, U.S.), Bioquell, An Ecolab Solution (Hampshire, U.K.), Terragene (Rosario, Argentina) and Other Market Players Top Players Covered in the Steam and Hydrogen Peroxide Biological Indicators Market Research Report are 3M (Minnesota, U.S.), STERIS (Ohio, United States), Getinge AB (Sweden), Cantel Medical (New Jersey, U.S.), Mesa Labs, Inc. (Colorado, United States), Tuttnauer (Hauppauge, U.S.), Bioquell, An Ecolab Solution (Hampshire, U.K.), Terragene (Rosario, Argentina) and Other Market Players
→ Google ترجمة
LAKEWOOD, Colo. (AP) _ Mesa Laboratories Inc. (MLAB) on Tuesday reported fiscal fourth-quarter net income of $3.9 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Lakewood, Colorado-based company said it had net income of 74 cents. Earnings, adjusted for amortization costs and stock option expense, came []
→ Google ترجمة
LAKEWOOD, Colo., June 01, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the fourth quarter (4Q21) and full year ended March 31, 2021 (FY21).
→ Google ترجمة
Mesa Laboratories, Inc. announced results for the fourth quarter and full year ended March 31, 2021.
→ Google ترجمة
Last week, the Seventh Circuit reminded advertisers of the narrowing availability of insurance coverage for Telephone Consumer Protection Act (TCPA) claims. In Mesa Laboratories v. Federal Insurance Co., the court rejected a fax marketers bid to make its insurer pay for its defense and settlement of an underlying unsolicited fax lawsuit. This decision underscores the insurance industrys recent trend of limiting TCPA coverage under general policy forms and requiring policyholders to seek out By: Kelley Drye & Warren LLP
→ Google ترجمة
Banks Tweak Bond Covenant Language To Protect Against Repeat Of Citi's $500M "Fat Finger" Loss After a court battle that dragged on for more than a year, a New York judge shocked the investment banking community last month when they ruled that a group of Revlon creditors could keep some $500MM that they refused to return to Citi after some $900MM was accidentally transferred in what appeared to be a "fat finger". At the time, legal experts posited that the judge's decision, which was based on quirks in New York State law, would force investment banks to reevaluate the wording of their bond covenants in all future deals, as the ruling created new risks that needed to be addressed. It appears America's biggest lenders have already come up with new legal terminology to be inserted into covenant agreements that would require lenders to return any accidentally transferred funds to the banks. The legally binding clauses have been inserted into debt deals for Eagle Materials and pet supply chain Petco, among other deals, the FT reports.
→ Google ترجمة
https://www.investing.com/news/stock-market-news/royce--associates-increased-stake-in-mesa-laboratories-inc-2400593
→ Google ترجمة
Mesa Laboratories Inc. shares closed today at 0.6% below its 52 week high of $297.01, giving the company a market cap of $1B. The stock is currently up 3.0% year-to-date, up 12.9% over the past 12 months, and up 262.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 1.5%. Trading Activity Trading volume this week was 1.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date lags the peer average by -46.3% The company's stock price performance over the past 12 months lags the peer average by -2.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google ترجمة
Mesa Laboratories Inc. shares closed today at 0.6% below its 52 week high of $297.01, giving the company a market cap of $1B. The stock is currently up 3.0% year-to-date, up 13.0% over the past 12 months, and up 262.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.1%, and the S&P 500 fell 0.2%. Trading Activity Trading volume this week was 1.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 0.2% higher than its 5-day moving average, 2.8% higher than its 20-day moving average, and 8.7% higher than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date lags the peer average by -48.1% The company's stock price performance over the past 12 months lags the peer average by -7.2%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google ترجمة
Mesa Laboratories Inc. shares closed today at 0.5% below its 52 week high of $296.79, giving the company a market cap of $1B. The stock is currently up 3.5% year-to-date, up 15.4% over the past 12 months, and up 261.0% over the past five years. This week, the Dow Jones Industrial Average rose 2.3%, and the S&P 500 rose 2.0%. Trading Activity Trading volume this week was 14.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date lags the peer average by -46.3% The company's stock price performance over the past 12 months lags the peer average by -11.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google ترجمة
Source: Mesa Laboratories, Inc. – June 16, 2020 11:30 AM ET Lakewood, Colo., June 16, 2020 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc….
→ Google ترجمة
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary
→ Google ترجمة
Mesa Labs (MLAB) delivered earnings and revenue surprises of -36.45% and -0.85%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
→ Google ترجمة
Lakewood, Colorado, April 1, 2020 - Mesa Laboratories, Inc. today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock…. | April 1, 2020
→ Google ترجمة
UPPSALA, Sweden--(BUSINESS WIRE)--Gyros Protein Technologies AB, a Mesa Laboratories, Inc. (NASDAQ:MLAB) company, and pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, and the Jefferson Institute for Bioprocessing (JIB) at Thomas Jefferson University, a leading center of excellence providing advanced training to the bioprocessing industry, today announced that Gyrolab xPlore™ immunoassay system from Gyros Protein Technologies will be in
→ Google ترجمة
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT … | February 12, 2020
→ Google ترجمة
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM… | February 12, 2020
→ Google ترجمة
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
→ Google ترجمة
Mesa Labs (MLAB) delivered earnings and revenue surprises of 7.18% and 2.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
→ Google ترجمة
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
→ Google ترجمة